BOOST Pharma ApS, a clinical-stage biopharmaceutical company focused on developing novel cell therapies for rare skeletal pediatric diseases.
The company’s lead therapy, BT-101, is designed to treat osteogenesis imperfecta (OI), a severe inherited condition that leads to significant physical disability. BOOST Pharma is supported by Industrifonden and Karolinska Development, Sweden.
Sound Bioventures has joined its investor syndicate with a SEK 34 million investment. The financing will support continued clinical development of BT-101, BOOST Pharma’s pioneering stem cell-based therapy for osteogenesis imperfecta (OI), also known as brittle bone disease.
